Chronic hepatitis B virus infection remains one of the most stubborn immunological challenges in medicine, largely because the CD8+ T cells that should destroy infected liver cells gradually lose their killing power. Now a team at the Institute of Microbiology of the Chinese Academy of Sciences, working with colleagues at Capital Medical University, has uncovered a molecular gatekeeper behind this decline. Reporting in Nature Immunology, Wei Xu and colleagues show that ANKRD11, a chromatin-associated protein, acts as a brake on CD8+ T cell effector differentiation, and that removing this brake dramatically enhances antiviral and antitumor immunity in mouse models.
The study began with a practical problem: researchers have lacked good tools to study the behavior of hepatitis B virus-specific T cells in a physiologically relevant setting. The team used a humanized mouse model carrying the human HLA-A11 molecule to identify a T cell receptor that recognizes HBc141-151, an epitope from the hepatitis B core antigen that is clinically relevant in human patients. This receptor, which the authors call HB-I, allowed them to generate transgenic mice whose entire CD8+ T cell population is specific for a single, human-relevant HBV epitope, providing a tractable platform for dissecting why these cells fail during chronic infection.
With that platform in hand, the researchers turned to an unbiased discovery strategy. Using a whole-genome CRISPR-Cas9 knockout library delivered into HBV-specific T cells, followed by screening under chronic antigen stimulation, they asked which genes, when deleted, would help T cells resist the dysfunctional state that normally develops. The screen converged on Ankrd11, a gene previously known as a chromatin regulator implicated in neural development and in Kabuki-like syndromes, but never before linked to T cell exhaustion. Loss of Ankrd11 consistently produced T cells that proliferated more vigorously and retained stronger effector characteristics.
The mechanistic picture that emerges from the paper is epigenetic. ANKRD11 appears to restrain the accessibility and acetylation of key effector genes. Using ATAC-seq, bulk RNA-seq and CUT&Tag profiling of the histone mark H3K27ac, the team showed that Ankrd11-deficient CD8+ T cells display increased chromatin openness and enhancer acetylation at loci encoding AP-1 family transcription factors, notably Fos and Fosb. Elevated AP-1 activity, in turn, drives a program of effector differentiation: the cells produce more granzyme B and interferon-gamma, resist the immunosuppressive conditions that normally silence them, and maintain function even when interleukin-2, a survival factor, is limiting.
Functionally, the consequences of losing this brake were striking. In mice carrying a replicating HBV plasmid or infected with recombinant HBV vectors, Ankrd11-deficient HBV-specific T cells expanded more robustly, infiltrated the liver more effectively, and drastically reduced serum levels of hepatitis B surface antigen, viral DNA and markers of liver damage. Parallel experiments using a second chronic infection model, lymphocytic choriomeningitis virus clone 13, confirmed the generality of the effect: adoptively transferred Ankrd11-deficient virus-specific P14 T cells showed enhanced granzyme expression, proliferation and viral control in the spleen and blood.
Perhaps the most conceptually interesting finding concerns the differentiation paths that exhausted T cells normally follow. In chronic infection and cancer, antigen-specific CD8+ T cells split into progenitor exhausted T cells, which express the transcription factor TCF-1 and serve as a self-renewing reservoir, and terminally exhausted T cells, which lose TCF-1 and are irreversibly dysfunctional. The authors found that Ankrd11 deficiency accelerates the conversion of progenitor exhausted cells into effector-like exhausted cells, but importantly, the resulting cells are cytotoxic and functional rather than inert. This suggests ANKRD11 does not simply maintain progenitor pools but actively gates how far exhausted cells differentiate toward effector competence.
The study also revealed a distinct route of reprogramming specific to chronic hepatitis B. A large fraction of HBV-specific CD8+ T cells in tolerant mice carries a PD-1-negative, TOX-negative phenotype that has resisted conventional checkpoint-based rescue strategies. When ANKRD11-mediated repression was relieved, these tolerant cells differentiated into PD-1-positive, KLRG1-positive effector cells armed with high granzyme levels, providing an explanation for the improved viral clearance. In other words, ANKRD11 deficiency unlocks an otherwise dormant pool of virus-specific cells that immune checkpoint blockade alone cannot reach.
The antitumor implications were tested directly in cancer models. Ankrd11-deficient CD8+ T cells promoted rejection of implanted tumors, enhanced intratumoral T cell activity, and acted synergistically with immune checkpoint blockade, potentiating the effect of PD-1 pathway inhibition. Given that the exhaustion of tumor-infiltrating lymphocytes is a central cause of immunotherapy failure, a single gene whose deletion reprograms effector differentiation under immunosuppressive conditions is an attractive candidate for therapeutic engineering, for example in chimeric antigen receptor or T cell receptor-engineered cell products. A provisional patent application has been filed based on the findings, underscoring the translational interest.
Caveats remain before ANKRD11 targeting reaches the clinic. ANKRD11 is a broad chromatin regulator with established roles in neural and cardiac development, so systemic inhibition is unlikely to be safe; the therapeutic window will probably lie in ex vivo engineering of T cells or in carefully targeted delivery. It will also be important to determine whether accelerated terminal differentiation comes at the cost of long-term memory formation. Nevertheless, the study delivers a clear conceptual advance: T cell dysfunction in chronic infection and cancer is not merely the product of inhibitory receptor signaling, but is epigenetically authored, and specific chromatin factors such as ANKRD11 can be removed to rewrite that script. For the hundreds of millions of people living with chronic hepatitis B, and for cancer patients whose T cells have gone quiet, that insight opens a new direction for immunotherapy design.
The concept of T cell exhaustion has shaped immunology for two decades. Since the landmark demonstration that chronically stimulated CD8+ T cells can regain function when inhibitory pathways are interrupted, researchers have catalogued a molecular signature of the dysfunctional state, and later work established the transcription factor TOX as a master architect of the exhaustion program, acting at both transcriptional and epigenetic levels. What has remained less clear is whether exhaustion is a fixed fate or a tunable state whose chromatin underpinnings can be deliberately rewritten. The new study adds weight to the second view by identifying a specific chromatin-associated protein whose removal shifts the balance of differentiation toward cytotoxic competence.
The methodological route to this finding is worth noting. Genome-wide CRISPR-Cas9 knockout screens have become a powerful way to uncover genes that constrain or enable T cell behavior, and previous efforts using this approach identified regulators such as REGNASE-1 and Roquin as suppressors of effector expansion and antitumor immunity. The present screen extends this logic into the setting of chronic hepatitis B virus infection, a context in which suppressive cues differ from those in tumors and in which conventional checkpoint blockade has shown only modest clinical benefit. That an unbiased screen converged on a gene with no prior immunological pedigree illustrates how phenotype-first discovery can bypass assumptions rooted in known pathways.
ANKRD11 itself carries an interesting dual history. It was first characterized as a chromatin regulator essential for neural development, and subsequent work showed it controls cardiac neural crest-mediated remodeling of the outflow tract. Its association with a Kabuki-like syndrome in humans reflects the pleiotropic consequences of disturbing a factor that operates broadly across tissues. This background both explains why the protein had escaped attention in immunology and reinforces the caution that any therapeutic interference must be confined to engineered cells rather than delivered systemically.
The AP-1 connection provides a mechanistic bridge to earlier T cell biology. AP-1 family transcription factors, built from Fos and Jun proteins, have long been recognized as immediate-early responders to T cell receptor signaling, and their activity is known to cooperate with other factors to specify effector genes. By showing that ANKRD11 restrains chromatin accessibility and H3K27 acetylation at AP-1 loci, the study suggests a route by which a chromatin regulator can gate a transcriptional program that is otherwise primed and waiting in naive and exhausted cells alike.
The authors have deposited the datasets underlying these conclusions in public repositories: bulk RNA-seq data under accession GSE299520, ATAC-seq data under GSE299519, and CUT&Tag data under GSE299521, with source data provided alongside the paper. No original code was generated. This transparency should allow groups working on T cell engineering to interrogate the chromatin changes directly and to test whether similar ANKRD11-sensitive programs operate in human tumor-infiltrating lymphocytes, a necessary step before the findings can inform next-generation cell therapy design.
Subject of Research: Epigenetic regulation of CD8+ T cell dysfunction in chronic viral infection and cancer
Article Title: ANKRD11 deficiency reprograms CD8+ T cell differentiation to enhance immunity in chronic infection and cancer
Article References: Xu, W., Guo, J., Cao, X., Li, L., Xiao, P., Zhang, X., Jin, Q., Zhang, F., Hou, B., Li, M., & Zhou, X. (2026). ANKRD11 deficiency reprograms CD8+ T cell differentiation to enhance immunity in chronic infection and cancer. Nature Immunology. https://doi.org/10.1038/s41590-026-02652-x
Image Credits: AI Generated
DOI: 10.1038/s41590-026-02652-x
Keywords: ANKRD11, CD8+ T cells, T cell exhaustion, chronic hepatitis B, epigenetics, immunotherapy, CRISPR screen, AP-1 transcription factors, granzyme B, immune checkpoint blockade, tumor immunity, T cell receptor
Cite Scienmag News
APA
MLA
Chicago
Kristina Jarvis. (September 12, 2026). Chromatin Regulator ANKRD11 Emerges as Switch That Reinvigorates Exhausted T Cells. Scienmag. https://scienmag.com/chromatin-regulator-ankrd11-emerges-as-switch-that-reinvigorates-exhausted-t-cells/
Kristina Jarvis. “Chromatin Regulator ANKRD11 Emerges as Switch That Reinvigorates Exhausted T Cells.” Scienmag, 12 September 2026, https://scienmag.com/chromatin-regulator-ankrd11-emerges-as-switch-that-reinvigorates-exhausted-t-cells/. Accessed 12 September 2026.
Kristina Jarvis. “Chromatin Regulator ANKRD11 Emerges as Switch That Reinvigorates Exhausted T Cells.” Scienmag. September 12, 2026. https://scienmag.com/chromatin-regulator-ankrd11-emerges-as-switch-that-reinvigorates-exhausted-t-cells/
Copy citation
Download RIS
Tags: ANKRD11antiviral immunity enhancementAP-1 transcription factorsCD8+ T cell exhaustionCD8+ T cellschromatin regulator ANKRD11chromatin-associated proteins in immune regulationchronic hepatitis BChronic hepatitis B immune responseCRISPR screenepigeneticsepitope-specific T cell responsegranzyme Bhumanized mouse models for hepatitis Bimmune checkpoint blockadeImmunotherapyimmunotherapy targets for chronic viral infectionsmolecular mechanisms of immune exhaustionT cell effector differentiationT cell exhaustionT cell receptorT cell receptor engineeringtumor immunity
